EA201100390A1 - Соединения для лечения гепатита с - Google Patents
Соединения для лечения гепатита сInfo
- Publication number
- EA201100390A1 EA201100390A1 EA201100390A EA201100390A EA201100390A1 EA 201100390 A1 EA201100390 A1 EA 201100390A1 EA 201100390 A EA201100390 A EA 201100390A EA 201100390 A EA201100390 A EA 201100390A EA 201100390 A1 EA201100390 A1 EA 201100390A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hepatitis
- connections
- treatment
- compounds
- hcv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Furan Compounds (AREA)
Abstract
Описание раскрывает соединения формулы I, включая их соли, так же как композиции и способы применения соединений. Соединения обладают активностью против вирусного гепатита С (HCV) и могут быть полезными для лечения пациентов, инфицированных HCV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9600508P | 2008-09-11 | 2008-09-11 | |
PCT/US2009/056166 WO2010030592A1 (en) | 2008-09-11 | 2009-09-08 | Compounds for the treatment of hepatitis c |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201100390A1 true EA201100390A1 (ru) | 2011-10-31 |
EA019185B1 EA019185B1 (ru) | 2014-01-30 |
Family
ID=41226922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201100390A EA019185B1 (ru) | 2008-09-11 | 2009-09-08 | Соединения для лечения гепатита с |
Country Status (19)
Country | Link |
---|---|
US (1) | US8048887B2 (ru) |
EP (1) | EP2326633B1 (ru) |
JP (1) | JP5685191B2 (ru) |
KR (1) | KR20110059875A (ru) |
CN (1) | CN102209717B (ru) |
AR (1) | AR073740A1 (ru) |
AU (1) | AU2009291966B2 (ru) |
BR (1) | BRPI0918174A2 (ru) |
CA (1) | CA2736988A1 (ru) |
CL (2) | CL2011000527A1 (ru) |
CO (1) | CO6382110A2 (ru) |
EA (1) | EA019185B1 (ru) |
IL (1) | IL211509A0 (ru) |
MX (1) | MX2011002410A (ru) |
NZ (1) | NZ591172A (ru) |
PE (1) | PE20110806A1 (ru) |
TW (2) | TW201014836A (ru) |
WO (1) | WO2010030592A1 (ru) |
ZA (2) | ZA201101739B (ru) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7994171B2 (en) * | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
WO2010051237A1 (en) * | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
SG177308A1 (en) * | 2009-06-22 | 2012-02-28 | Hoffmann La Roche | Novel biphenyl and phenyl-pyridine amides |
BR112012006572A2 (pt) | 2009-09-25 | 2016-04-26 | Oryzon Genomics Sa | inibidores de demetilase-1 de lisina específicos e seu uso |
US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
US8324212B2 (en) | 2010-02-25 | 2012-12-04 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
TW201136919A (en) * | 2010-03-02 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | Inhibitors of hepatitis C virus NS5B polymerase |
CN102906080A (zh) * | 2010-03-11 | 2013-01-30 | 百时美施贵宝公司 | 治疗丙型肝炎的化合物 |
US8354410B2 (en) | 2010-03-11 | 2013-01-15 | Bristol-Meyers Squibb Company | Compounds for the treatment of hepatitis C |
WO2011131697A1 (en) | 2010-04-19 | 2011-10-27 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
EP2566333A4 (en) * | 2010-05-07 | 2014-04-02 | Univ Leland Stanford Junior | IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS |
US8445497B2 (en) * | 2010-06-30 | 2013-05-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
EP3375775A1 (en) | 2010-07-29 | 2018-09-19 | Oryzon Genomics, S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
EP2963034A1 (en) | 2010-08-26 | 2016-01-06 | RFS Pharma, LLC. | Potent and selective inhibitors of hepatitis c virus |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
NZ609564A (en) | 2010-10-26 | 2015-06-26 | Presidio Pharmaceuticals Inc | Inhibitors of hepatitis c virus |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
US8507683B2 (en) * | 2010-12-09 | 2013-08-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
JP5918264B2 (ja) | 2010-12-22 | 2016-05-18 | アッヴィ・インコーポレイテッド | C型肝炎阻害剤およびその使用 |
WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) * | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
WO2013033900A1 (en) * | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
BR112014009238B1 (pt) | 2011-10-20 | 2022-08-09 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina, seus usos e composições farmacêuticas |
EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
US9303020B2 (en) | 2012-02-08 | 2016-04-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
WO2013148620A1 (en) | 2012-03-27 | 2013-10-03 | Bristol-Myers Squibb Company | Benzofuran derivatives for the treatment of hepatitis c |
WO2013163466A1 (en) * | 2012-04-25 | 2013-10-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
EP2943496B1 (en) * | 2013-01-10 | 2017-09-06 | Bristol-Myers Squibb Company | Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c |
WO2014121416A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
US8962651B2 (en) | 2013-03-13 | 2015-02-24 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
WO2014159559A1 (en) * | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Fused furans for the treatment of hepatitis c |
WO2014205593A1 (en) | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
EP3080106B1 (en) | 2013-12-13 | 2018-01-31 | Bristol-Myers Squibb Company | A novel compound for the treatment of hepatitis c |
EP3119769A1 (en) * | 2014-03-21 | 2017-01-25 | Bristol-Myers Squibb Pharma Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c |
ES2688554T3 (es) * | 2014-03-21 | 2018-11-05 | Bristol-Myers Squibb Company | Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis C |
US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
US10131645B2 (en) | 2015-02-19 | 2018-11-20 | Bristol-Myers Squibb Company | Benzofurans substituted with primary benzamide as HCV inhibitors |
US10570108B2 (en) | 2015-02-19 | 2020-02-25 | Bristol-Myers Squibb Company | Substituted benzofuran compounds for the treatment of hepatitis C |
WO2016133961A1 (en) * | 2015-02-19 | 2016-08-25 | Bristol-Myers Squibb Company | Benzofurans substituted with bicyclic secondary benzamide as hcv inhibitors |
US10087167B2 (en) | 2015-02-19 | 2018-10-02 | Bristol-Myers Squibb Company | Benzofurans substituted with secondary benzamide as HCV inhibitors |
EP3262038A1 (en) | 2015-02-23 | 2018-01-03 | Bristol-Myers Squibb Company | Novel compounds for the treatment of hepatitis c |
WO2017165233A1 (en) * | 2016-03-21 | 2017-09-28 | Bristol-Myers Squibb Company | Benzofuran derivatives for the treatment of hepatitis c |
IL268683B2 (en) | 2017-02-17 | 2023-04-01 | Eidos Therapeutics Inc | Processes for the preparation of ag-10, its intermediates and salts |
KR102512548B1 (ko) | 2017-12-22 | 2023-03-22 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물 |
MX2020009844A (es) | 2018-03-23 | 2021-01-15 | Eidos Therapeutics Inc | Metodos para tratar amiloidosis por transtiretina (ttr) usando ag10. |
WO2020037189A1 (en) | 2018-08-17 | 2020-02-20 | Eidos Therapeutics, Inc. | Formulations of ag10 |
AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
WO2021008512A1 (zh) * | 2019-07-18 | 2021-01-21 | 石药集团中奇制药技术(石家庄)有限公司 | 作为nmt抑制剂的化合物及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57123181A (en) | 1981-01-23 | 1982-07-31 | Mitsubishi Paper Mills Ltd | Preparation of pyrazolo (1,5-a) pyridine derivative |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
JP2004525150A (ja) | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
EP1581207A4 (en) * | 2002-11-01 | 2007-07-25 | Viropharma Inc | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING AND PROPHYLAXIS OF VIRAL INFECTIONS WITH HEPATITIS C AND RELATED ILLNESSES |
US7868037B2 (en) * | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
TW200815384A (en) * | 2006-08-25 | 2008-04-01 | Viropharma Inc | Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein |
WO2008100867A2 (en) * | 2007-02-12 | 2008-08-21 | Intermune, Inc. | Novel inhibitors hepatitis c virus replication |
GB0707000D0 (en) | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
CA2714254A1 (en) | 2008-02-14 | 2009-08-20 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
WO2009137500A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
WO2009137493A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 2-substituted benzofuran compounds to treat infection with hepatitis c virus |
-
2009
- 2009-09-04 US US12/554,193 patent/US8048887B2/en active Active
- 2009-09-08 AU AU2009291966A patent/AU2009291966B2/en not_active Ceased
- 2009-09-08 KR KR1020117008085A patent/KR20110059875A/ko not_active Application Discontinuation
- 2009-09-08 PE PE2011000445A patent/PE20110806A1/es active IP Right Grant
- 2009-09-08 BR BRPI0918174A patent/BRPI0918174A2/pt not_active IP Right Cessation
- 2009-09-08 JP JP2011526931A patent/JP5685191B2/ja not_active Expired - Fee Related
- 2009-09-08 CA CA2736988A patent/CA2736988A1/en not_active Abandoned
- 2009-09-08 MX MX2011002410A patent/MX2011002410A/es active IP Right Grant
- 2009-09-08 WO PCT/US2009/056166 patent/WO2010030592A1/en active Application Filing
- 2009-09-08 NZ NZ591172A patent/NZ591172A/xx not_active IP Right Cessation
- 2009-09-08 EP EP09792299.1A patent/EP2326633B1/en not_active Not-in-force
- 2009-09-08 CN CN200980144912.3A patent/CN102209717B/zh not_active Expired - Fee Related
- 2009-09-08 EA EA201100390A patent/EA019185B1/ru not_active IP Right Cessation
- 2009-09-11 TW TW098130829A patent/TW201014836A/zh unknown
- 2009-09-11 AR ARP090103514A patent/AR073740A1/es not_active Application Discontinuation
- 2009-09-11 TW TW100113021A patent/TW201124403A/zh unknown
-
2011
- 2011-03-01 IL IL211509A patent/IL211509A0/en unknown
- 2011-03-01 ZA ZA2011/01739A patent/ZA201101739B/en unknown
- 2011-03-11 CL CL2011000527A patent/CL2011000527A1/es unknown
- 2011-04-05 CO CO11041979A patent/CO6382110A2/es not_active Application Discontinuation
- 2011-05-25 CL CL2011001224A patent/CL2011001224A1/es unknown
- 2011-08-03 ZA ZA2011/05720A patent/ZA201105720B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201101739B (en) | 2012-08-29 |
CN102209717B (zh) | 2015-02-18 |
CO6382110A2 (es) | 2012-02-15 |
US20100093694A1 (en) | 2010-04-15 |
ZA201105720B (en) | 2012-08-29 |
TW201124403A (en) | 2011-07-16 |
MX2011002410A (es) | 2011-04-05 |
KR20110059875A (ko) | 2011-06-07 |
EP2326633A1 (en) | 2011-06-01 |
JP5685191B2 (ja) | 2015-03-18 |
AU2009291966A1 (en) | 2010-03-18 |
JP2012502101A (ja) | 2012-01-26 |
PE20110806A1 (es) | 2011-10-31 |
AU2009291966B2 (en) | 2014-08-28 |
BRPI0918174A2 (pt) | 2019-10-01 |
CL2011000527A1 (es) | 2011-08-12 |
IL211509A0 (en) | 2011-07-31 |
AR073740A1 (es) | 2010-12-01 |
TW201014836A (en) | 2010-04-16 |
US8048887B2 (en) | 2011-11-01 |
EP2326633B1 (en) | 2015-12-16 |
WO2010030592A1 (en) | 2010-03-18 |
EA019185B1 (ru) | 2014-01-30 |
CL2011001224A1 (es) | 2011-09-16 |
CN102209717A (zh) | 2011-10-05 |
NZ591172A (en) | 2012-12-21 |
CA2736988A1 (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201100390A1 (ru) | Соединения для лечения гепатита с | |
MX2012004032A (es) | Compuestos para el tratamiento de hepatitis c. | |
WO2010030538A3 (en) | Compounds for the treatment of hepatitis c | |
EA200901241A1 (ru) | Соединения для лечения гепатита с | |
MX2010008699A (es) | Derivados heterociclicos como inhibidores de virus de la hepatitis c. | |
EA200900298A1 (ru) | Ингибиторы вируса гепатита с | |
EA201390822A1 (ru) | Макроциклические ингибиторы вирусов flaviviridae | |
NZ595186A (en) | Di-pyrazolidinyl-biphenylyl compounds for treating hepatitis C virus (HCV) infection | |
ATE551343T1 (de) | Tetracyclische verbindungen zur behandlung von hepatitis c | |
ATE469155T1 (de) | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer | |
ATE483712T1 (de) | Hcv-ns5b-inhibitoren | |
EA201290575A1 (ru) | Ингибиторы вирусов flaviviridae | |
ATE547103T1 (de) | Hemmer des hepatitis-c-virus | |
CY1112999T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
EA201270656A1 (ru) | Ингибиторы вируса гепатита с | |
DK2250163T3 (da) | Hepatitis C-virusinhibitorer | |
EA201290576A1 (ru) | Ингибиторы вирусов flaviviridae | |
EA200702493A1 (ru) | Соединения и способы лечения или предотвращения флавивирусных инфекций | |
EA201270616A1 (ru) | Ингибиторы вируса гепатита с | |
EA201290053A1 (ru) | Ингибиторы вирусов flaviviridae | |
ATE522532T1 (de) | Verbindungen zur behandlung von hepatitis c | |
DE602008004317D1 (de) | Verbindungen zur behandlung von hepatitis c | |
DK2209789T3 (da) | Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere | |
MX2010001416A (es) | Compuesto para el tratamiento de la hepatitis c. | |
ATE505473T1 (de) | Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |